Immunotherapy in Squamous Cell Cancer of the Esophagus
Standard
Immunotherapy in Squamous Cell Cancer of the Esophagus. / Thuss-Patience, Peter; Stein, Alexander.
In: CURR ONCOL, Vol. 29, No. 4, 30.03.2022, p. 2461-2471.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Immunotherapy in Squamous Cell Cancer of the Esophagus
AU - Thuss-Patience, Peter
AU - Stein, Alexander
PY - 2022/3/30
Y1 - 2022/3/30
N2 - Treatment of esophageal carcinoma has changed dramatically following several landmark trials, which have proven the benefit of immunotherapy. The selective PD-1 (programmed cell death ligand-1)-inhibitor nivolumab has been shown to improve DFS in the adjuvant therapy setting (CheckMate-577). In the first-line treatment, PD-L1 positive (CPS ≥ 10) squamous cell carcinoma patients (pts) have been shown to have an increased OS following treatment with the PD-1-inhibitor pembrolizumab in combination with chemotherapy (KEYNOTE-590). Nivolumab also improved overall survival in the first line setting either combined with ipilimumab or with chemotherapy (CheckMate 648) compared to chemotherapy alone. In Asian first-line patients, phase III trials investigating camrelizumab (ESCORT 1), toripalimab (JUPITER 06), or sintilimab (ORIENT 15) in addition to chemotherapy also showed significant survival benefits. In the second-line setting, monotherapy with nivolumab (ATTRACTION-03), pembrolizumab (KEYNOTE-181), camrelizumab (ESCORT), and tislelizumab (RATIONALE 302) demonstrated a benefit in OS in comparison to chemotherapy. Here we will review these trials and integrate them into the current treatment algorithm.
AB - Treatment of esophageal carcinoma has changed dramatically following several landmark trials, which have proven the benefit of immunotherapy. The selective PD-1 (programmed cell death ligand-1)-inhibitor nivolumab has been shown to improve DFS in the adjuvant therapy setting (CheckMate-577). In the first-line treatment, PD-L1 positive (CPS ≥ 10) squamous cell carcinoma patients (pts) have been shown to have an increased OS following treatment with the PD-1-inhibitor pembrolizumab in combination with chemotherapy (KEYNOTE-590). Nivolumab also improved overall survival in the first line setting either combined with ipilimumab or with chemotherapy (CheckMate 648) compared to chemotherapy alone. In Asian first-line patients, phase III trials investigating camrelizumab (ESCORT 1), toripalimab (JUPITER 06), or sintilimab (ORIENT 15) in addition to chemotherapy also showed significant survival benefits. In the second-line setting, monotherapy with nivolumab (ATTRACTION-03), pembrolizumab (KEYNOTE-181), camrelizumab (ESCORT), and tislelizumab (RATIONALE 302) demonstrated a benefit in OS in comparison to chemotherapy. Here we will review these trials and integrate them into the current treatment algorithm.
KW - Carcinoma, Squamous Cell/drug therapy
KW - Epithelial Cells
KW - Esophageal Neoplasms/drug therapy
KW - Humans
KW - Immunologic Factors/therapeutic use
KW - Immunotherapy
KW - Nivolumab/therapeutic use
KW - Programmed Cell Death 1 Receptor
U2 - 10.3390/curroncol29040200
DO - 10.3390/curroncol29040200
M3 - SCORING: Review article
C2 - 35448174
VL - 29
SP - 2461
EP - 2471
JO - CURR ONCOL
JF - CURR ONCOL
SN - 1198-0052
IS - 4
ER -